Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA lifts Telcyta hold

Telik (TELK) gained $0.48 (14%) to $3.94 on Monday after announcing that

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE